These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7593435)

  • 21. Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course.
    Avila NA; Shawker TH; Roach P; Bradford MH; Skarulis MC; Eastman R
    J Clin Ultrasound; 1998; 26(6):289-94. PubMed ID: 9641388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
    Trendle MC; Moertel CG; Kvols LK
    Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.
    Catnach SM; Anderson JV; Fairclough PD; Trembath RC; Wilson PA; Parker E; Besser GM; Wass JA
    Gut; 1993 Feb; 34(2):270-3. PubMed ID: 8432484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.
    Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH
    Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.
    Erlinger S; Chanson P; Dumont M; Ponsot P; Warnet A; Harris AG
    Dig Dis Sci; 1994 Nov; 39(11):2384-8. PubMed ID: 7956607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Wass JA
    Digestion; 1993; 54 Suppl 1():107-20. PubMed ID: 8103009
    [No Abstract]   [Full Text] [Related]  

  • 32. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones.
    Veysey MJ; Thomas LA; Mallet AI; Jenkins PJ; Besser GM; Wass JA; Murphy GM; Dowling RH
    Gut; 1999 May; 44(5):675-81. PubMed ID: 10205204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss.
    Worobetz LJ; Inglis FG; Shaffer EA
    Am J Gastroenterol; 1993 Oct; 88(10):1705-10. PubMed ID: 8213711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octreotide increases the proportions of arachidonic acid-rich phospholipids in gall-bladder bile.
    Pereira SP; Hussaini SH; Murphy GM; Wass JA; Dowling RH
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1435-43. PubMed ID: 11552916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.
    Weeke J; Christensen SE; Orskov H; Kaal A; Pedersen MM; Illum P; Harris AG
    J Clin Endocrinol Metab; 1992 Jul; 75(1):163-9. PubMed ID: 1619006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An observation of the secretion of growth hormone and contraction of gall bladder after long-term use of growth-inhibition excitants].
    Zhu XF; Shi YF; Gao SM
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):87-91. PubMed ID: 8070297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
    Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
    Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.